New Vernon Capital Holdings Ii LLC Gilead Sciences, Inc. Transaction History

New Vernon Capital Holdings Ii LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $24,551 - $29,940	343 New	343 $25,000
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $173,910 - $198,369	-2,288 Reduced 66.92%	1,131 $87,000
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $136,942 - $156,423	-2,300 Reduced 40.22%	3,419 $211,000
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $330,100 - $371,792	5,719 New	5,719 $353,000
Q1 2019 May 13, 2019	SELL	$62.53 - $70.05 $317,089 - $355,223	-5,071 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$60.54 - $79.0 $81,668 - $106,571	1,349 Added 36.24%	5,071 $317,000
Q3 2018 Nov 13, 2018	BUY	$71.28 - $78.92 $1,283 - $1,420	18 Added 0.49%	3,722 $287,000
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $240,315 - $280,318	3,704 New	3,704 $262,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of New Vernon Capital Holdings Ii LLC, based on Form 13F filings with the SEC.

Stay updated on New Vernon Capital Holdings Ii LLC with notifications on news.